rs743572

A SNP in the CYP17A1 gene on chromosome 10. Its most notable genotype is A;A: common in clinvar

Gene
CYP17A1
Location
Chr 10102,837,395 (GRCh38)
Highest magnitude
0.0Typical
Tested on
23andMe, AncestryDNA, FamilyTreeDNA
Minor allele frequency
42%

Genotypes

As shown in 23andMe and AncestryDNA files.

  1. A;AMost notableGoodcommon in clinvarTypical · 0.035% of people

On SNPedia: (A;A). Magnitude rates how notable a genotype is from 0 to 10, not how risky it is.

Frequency

Share of each genotype in 11 HapMap populations.

  • AverageA;A 35%
  • European ancestry (Utah)A;A 40%
  • Han Chinese (Beijing)A;A 18%
  • Japanese (Tokyo)A;A 30%
  • Yoruba (Nigeria)A;A 52%
  • African ancestry (Southwest US)A;A 33%
  • Chinese (Denver)A;A 16%
  • Gujarati IndianA;A 36%
  • Luhya (Kenya)A;A 54%
  • Mexican ancestry (Los Angeles)A;A 37%
  • Maasai (Kenya)A;A 38%
  • TuscanA;A 37%

Notes

From SNPedia

Show notes, about 470 words

rs743572, known best as the CYP17 -34 T/C or T>C variant, is a variant in the 5' upstream region of the CYP17A1 gene. CYP17 genotype is associated with short menstrual cycles, early oral contraceptive use and BRCA mutation status in young healthy women. Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk. The rs743572 common variant in the promoter of CYP17A1 is not associated with prostate cancer risk or circulating hormonal levels. CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study. Genetic variation in CYP17 and endometrial cancer risk. Variants in hormone biosynthesis genes and risk of endometrial cancer. Polymorphisms in steroid hormone biosynthesis genes and risk of breast cancer and fibrocystic breast conditions in Chinese women. Polymorphisms of CYP17A1, CYP19, and androgen in Brazilian women with uterine leiomyomas. Functional genetic polymorphisms and female reproductive disorders: Part I: Polycystic ovary syndrome and ovarian response. Polymorphisms in genes involved in sex hormone metabolism, estrogen plus progestin hormone therapy use, and risk of postmenopausal breast cancer. Association of genetic polymorphisms of ER-alpha and the estradiol-synthesizing enzyme genes CYP17 and CYP19 with breast cancer risk in Chinese women. Functional genetic polymorphisms and female reproductive disorders: part II--endometriosis. Polymorphisms in estrogen- and androgen-metabolizing genes and the risk of gastric cancer. Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. Tobacco and estrogen metabolic polymorphisms and risk of non-small cell lung cancer in women. Genetic polymorphisms of FSHR, CYP17, CYP1A1, CAPN10, INSR, SERPINE1 genes in adolescent girls with polycystic ovary syndrome. African American-preponderant single nucleotide polymorphisms (SNPs) and risk of breast cancer. Solitary and multiple uterine leiomyomas among Caucasian women: two different disorders? Common Variation in the CYP17A1 and IFIT1 Genes on Chromosome 10 Does Not Contribute to the Risk of Endometriosis. The CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers. CYP17 gene polymorphisms and prostate cancer risk: A meta-analysis based on 38 independent studies. [Association of single nucleotide polymorphism in CYP17 and ERalpha genes with endometriosis risk in southern Chinese women]. CYP17 gene polymorphisms and prostate cancer risk: a meta-analysis based on 38 independent studies.

Source and license

Adapted from rs743572 on SNPedia, using a snapshot taken October 16, 2026. SNPedia content is shared under CC BY-NC-SA 3.0 US, and this page is shared under the same license.

SNPedia is a community-edited wiki. Its entries can be incomplete, out of date or wrong, and nothing here is a diagnosis or medical advice. Magnitude is a community rating of how interesting a genotype is, not a risk score.